Improving treatment intensification to reduce cardiovascular disease risk: a cluster randomized trial

[1]  Paul E. Johnson,et al.  Impact of Electronic Health Record Clinical Decision Support on Diabetes Care: A Randomized Trial , 2011, The Annals of Family Medicine.

[2]  J. Graff Zivin,et al.  US Pharmacists' Effect as Team Members on Patient Care: Systematic Review and Meta-Analyses , 2010, Medical care.

[3]  J. Selby,et al.  The impact of removing financial incentives from clinical quality indicators: longitudinal analysis of four Kaiser Permanente indicators , 2010, BMJ : British Medical Journal.

[4]  J. Selby,et al.  Meaningful Variation in Performance: What Does Variation in Quality Tell Us About Improving Quality? , 2010, Medical care.

[5]  Benjamin Littenberg,et al.  The Vermont Diabetes Information System: A Cluster Randomized Trial of a Population Based Decision Support System , 2009, Journal of General Internal Medicine.

[6]  Shimin Zheng,et al.  The potency of team-based care interventions for hypertension: a meta-analysis. , 2009, Archives of internal medicine.

[7]  Jim Bellows,et al.  Preventing myocardial infarction and stroke with a simplified bundle of cardioprotective medications. , 2009, The American journal of managed care.

[8]  W. Herman,et al.  Effect of a managed care disease management program on diabetes care. , 2009, The American journal of managed care.

[9]  Suzanne Austin Boren,et al.  Computerized Prompting and Feedback of Diabetes Care: A Review of the Literature , 2009, Journal of diabetes science and technology.

[10]  Ellen Meara,et al.  Differences in Control of Cardiovascular Disease and Diabetes by Race, Ethnicity, and Education: U.S. Trends From 1999 to 2006 and Effects of Medicare Coverage , 2009, Annals of Internal Medicine.

[11]  Julie A Schmittdiel,et al.  Treatment Intensification and Risk Factor Control: Toward More Clinically Relevant Quality Measures , 2009, Medical care.

[12]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[13]  M. Pladevall,et al.  When More Is Not Better: Treatment Intensification Among Hypertensive Patients With Poor Medication Adherence , 2008, Circulation.

[14]  David W. Bates,et al.  Impact of Computerized Decision Support on Blood Pressure Management and Control: A Randomized Controlled Trial , 2008, Journal of General Internal Medicine.

[15]  A. Karter,et al.  Why Don’t Diabetes Patients Achieve Recommended Risk Factor Targets? Poor Adherence versus Lack of Treatment Intensification , 2008, Journal of General Internal Medicine.

[16]  K. Shojania,et al.  Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. , 2006, JAMA.

[17]  Vandana Sundaram,et al.  Quality Improvement Strategies for Hypertension Management: A Systematic Review , 2006, Medical care.

[18]  E. Vittinghoff,et al.  Therapy Modifications in Response to Poorly Controlled Hypertension, Dyslipidemia, and Diabetes Mellitus , 2006, Annals of Internal Medicine.

[19]  M. Engelgau,et al.  Improvements in Diabetes Processes of Care and Intermediate Outcomes: United States, 19882002 , 2006, Annals of Internal Medicine.

[20]  Paul Kolm,et al.  An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting: Improving Primary Care of African Americans with Diabetes (IPCAAD) 8. , 2006, Archives of internal medicine.

[21]  A. Lippman.  Adherence to medication. , 2005, The New England journal of medicine.

[22]  Aneel A. Advani,et al.  Improving adherence to guidelines for hypertension drug prescribing: cluster-randomized controlled trial of general versus patient-specific recommendations. , 2005, The American journal of managed care.

[23]  Curtiss B. Cook,et al.  Clinical Inertia Contributes to Poor Diabetes Control in a Primary Care Setting , 2005, The Diabetes educator.

[24]  Richard W Grant,et al.  Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. , 2005, Diabetes care.

[25]  Michael Kelleher,et al.  Hypertension management: the care gap between clinical guidelines and clinical practice. , 2004, The American journal of managed care.

[26]  G. Nichols,et al.  Slow response to loss of glycemic control in type 2 diabetes mellitus. , 2003, The American journal of managed care.

[27]  C. Sueta,et al.  Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure. , 2003, Journal of cardiac failure.

[28]  O. Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[29]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[30]  A. Gotto,et al.  Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction , 2002, Vascular medicine.

[31]  M. Weinstein,et al.  Long-term persistence in use of statin therapy in elderly patients. , 2002, JAMA.

[32]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[33]  Ward Hj.  Inadequate management of blood pressure in a hypertensive population. , 1999, The New England journal of medicine.

[34]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[35]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[36]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[37]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[38]  M. Young,et al.  Health services research , 2008, Journal of General Internal Medicine.

[39]  W. Elliott,et al.  Improving Blood Pressure Control through Provider Education, Provider Alerts, and Patient Education: A Cluster Randomized TrialRoumie CL, Elasy TA, Greevy R, et al (Vanderbilt Univ, Nashville, Tenn; VA Med Ctr, Nashville, Tenn): Ann Intern Med 145:165–175, 2006§ , 2007 .

[40]  Eric J Topol,et al.  Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. , 2004, JAMA.

[41]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .